Lung Cancer Trials - ILD

I don't know whether it's because there's so much, you know, pulmonary issues already with the typical lung cancer patients. But I kind of get the feeling that the lung people aren't as concerned about it. Half of your colleagues right now would like to give TDXD first line. In terms of ILD, it's not benign. It could be certainly fatal. Our destiny lungoone trials had reported the fatality. So did most TDXD trials, except destiny breast 03,. which gave it early line with extensive education and early intervention program that actually made the difference.